- Morgan Stanley analyst Matthew Harrison writes that a patent case filed by REGENXBIO Inc. (NASDAQ:RGNX) against Sarepta Therapeutics (NASDAQ:SRPT) regarding SRP-9001 and SRP-9003 could have implications for the company.
- In late December, a federal judge denied a motion from Sarepta Therpeutics (SRPT) to dismiss a lawsuit filed by Wilson Wolf Manufacturing Corp. regarding SRP-9001.
- Harrison notes that REGENEXBIO "may be able to obtain a higher royalty based on its AAV patent (a mid-to-high single-digit royalty) than Wilson Wolf can likely obtain based on its cell-culture-device patent (a low single-digit royalty)."
- Sarepta has also filed a motion to dismiss the REGENXBIO case.
- Harrison maintains an equal-weight rating on the stock and a $95 price target.
- Sarepta shares are down 1.3% to $94.07 and REGENXBIO shares are down 2.3% to $47.61 in afternoon trading.